Mulé J J, Shu S, Schwarz S L, Rosenberg S A
Science. 1984 Sep 28;225(4669):1487-9. doi: 10.1126/science.6332379.
The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) of these tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.
用白细胞介素-2（IL-2）激活人外周血白细胞或小鼠脾细胞，可产生在体外对多种新鲜肿瘤细胞具有杀伤作用的细胞。当将这种淋巴因子激活的杀伤（LAK）细胞过继转移到已发生肺肉瘤转移的小鼠体内，并联合重复注射重组IL-2时，能非常有效地减少这些肿瘤结节的数量（和大小）。这些发现为进行用重组IL-2产生的人LAK细胞输注的临床试验以及将重组IL-2全身输注到人体的I期试验提供了理论依据。
